These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 23969938)

  • 81. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
    Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
    Damnernsawad A; Bottomly D; Kurtz SE; Eide CA; McWeeney SK; Tyner JW; Nechiporuk T
    Haematologica; 2022 Jan; 107(1):77-85. PubMed ID: 33375770
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
    Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
    Lee JH; Shin JE; Kim W; Jeong P; Kim MJ; Oh SJ; Lee HJ; Park HW; Han SY; Kim YC
    Eur J Med Chem; 2022 Jul; 237():114356. PubMed ID: 35489222
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
    Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
    Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
    Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
    Ruan M; Wang YQ; Zhang L; Liu TF; Liu F; Liu XM; Zhang JY; Zou Y; Chen YM; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):863-6. PubMed ID: 22099191
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
    Hu B; Vikas P; Mohty M; Savani BN
    Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
    von Bubnoff N; Rummelt C; Menzel H; Sigl M; Peschel C; Duyster J
    Leukemia; 2010 Aug; 24(8):1523-5. PubMed ID: 20520641
    [No Abstract]   [Full Text] [Related]  

  • 95. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.
    Ma H; Nguyen B; Li L; Greenblatt S; Williams A; Zhao M; Levis M; Rudek M; Duffield A; Small D
    Blood; 2014 Mar; 123(10):1525-34. PubMed ID: 24408321
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
    Jiang ZH; Feng FE; Lin XQ; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):736. PubMed ID: 23978034
    [No Abstract]   [Full Text] [Related]  

  • 97. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
    Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
    Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
    [TBL] [Abstract][Full Text] [Related]  

  • 99. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 100. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.